A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01110421
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT01110408
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT01110382
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 344
- Registration Number
- NCT01106690
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 469
- Registration Number
- NCT01106625
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 716
- Registration Number
- NCT01106651
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1284
- Registration Number
- NCT01106677
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT01090427
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 678
- Registration Number
- NCT01081834
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 312
- Registration Number
- NCT01077362
© Copyright 2024. All Rights Reserved by MedPath